The CGM Boom Beyond Diabetes
Walk into any biohacking meetup, CrossFit gym, or Silicon Valley office and you will spot them — small circular sensors adhered to the backs of arms, quietly tracking blood glucose levels in real time. Continuous glucose monitors (CGMs), originally developed for people with diabetes who need to manage insulin dosing, have become one of the hottest wellness trends of 2026, embraced by health-conscious individuals who have never had a blood sugar problem.
The market for non-diabetic CGM use has grown from virtually nothing five years ago to an estimated $1.2 billion annually, driven by direct-to-consumer companies like Levels, Nutrisense, and January AI that pair the hardware with coaching apps and subscription services. Even traditional CGM manufacturers are eyeing this demographic — Abbott launched the Lingo biosensor specifically for the wellness market, and Dexcom's over-the-counter Stelo is available without a prescription.
What Non-Diabetic Users Are Tracking
For people without diabetes, the appeal of CGM lies in understanding how different foods, exercise patterns, sleep quality, and stress levels affect blood glucose in real time. Users report making dietary changes based on observing post-meal glucose spikes — choosing sweet potatoes over white rice, for example, or timing carbohydrate intake around workouts.
Proponents argue that even within the "normal" blood sugar range (fasting glucose below 100 mg/dL, post-meal glucose below 140 mg/dL), there is meaningful variation that can inform healthier choices. They point to research suggesting that minimizing glucose variability and reducing post-meal spikes may have long-term benefits for metabolic health, inflammation, and cognitive function.
Popular use cases among non-diabetic CGM users include:
- Identifying foods that cause personal glucose spikes (glucose responses to the same food vary significantly between individuals)
- Optimizing meal timing and composition for sustained energy
- Tracking the glucose-lowering effects of exercise
- Monitoring the metabolic impact of sleep deprivation and stress
- Preventing progression from normal glucose tolerance to prediabetes
What Endocrinologists Say
The medical community is divided on whether CGMs provide meaningful benefits for people with normal glucose metabolism. Supporters see potential for early detection of metabolic dysfunction and behavior change motivation. Skeptics worry about unnecessary medicalization of normal physiology, anxiety-driven dietary restriction, and the diversion of devices and clinical attention from diabetic patients who need them.
"For my patients with diabetes, CGM is transformative. For a healthy 28-year-old who exercises regularly and eats well, I worry we're turning normal glucose fluctuations into a source of anxiety," said Dr. Anne Peters, professor of clinical medicine at the University of Southern California Keck School of Medicine and a leading diabetes specialist.
Dr. Peters notes that blood glucose naturally rises after eating — that is how the body works. A post-meal reading of 160 mg/dL in a non-diabetic person is a normal physiological response, not a disease state. She worries that without proper context, CGM data can lead people to unnecessarily restrict carbohydrates, develop disordered eating patterns, or seek medical treatment they do not need.
The Case For Non-Diabetic CGM Use
Other physicians are more enthusiastic. Dr. Casey Means, a Stanford-trained physician and co-founder of Levels, argues that the current diagnostic framework — which labels people as "healthy" until their fasting glucose crosses the 100 mg/dL threshold — misses a large population of metabolically unhealthy individuals.
Research published in The Lancet in 2024 found that approximately 93 million American adults have prediabetes, and most of them do not know it. Standard blood tests performed at annual physicals can miss early metabolic dysfunction because they capture only a single moment rather than the dynamic glucose responses throughout the day.
Studies have shown that even among people with "normal" lab results, there is significant variation in glucose responses. Some individuals spike to diabetic-range glucose levels after eating common foods and return to normal before their next fasting blood draw would catch it.
Cost and Accessibility Considerations
For non-diabetic users, CGM is an entirely out-of-pocket expense. The sensors themselves cost $75 to $150 for a 14-day sensor, and most subscription services add $150 to $200 per month for app access and coaching. Annual costs can easily exceed $2,000 — a significant investment that raises equity concerns about who can access this type of metabolic insight.
Insurance coverage for CGM remains limited to diabetic patients and, in some plans, those with prediabetes. Unless coverage policies expand, the technology risks becoming another tool that widens the health gap between affluent and lower-income Americans.
A Middle Ground
Many clinicians advocate for a middle-ground approach: short-term CGM use (two to four weeks) as an educational tool, rather than indefinite continuous monitoring. A brief period of glucose tracking can reveal personal dietary patterns and inform lasting behavior changes, after which the device can be discontinued without losing the insights gained.
This approach balances the legitimate benefits of personalized glucose data against the risks of health anxiety, unnecessary cost, and over-medicalization. As CGM technology continues to become cheaper and more accessible, finding this balance will be increasingly important for both individuals and the healthcare system.
